The Affordable Prescriptions for Patients Act aims to make it easier for companies to sell cheaper versions of biologic drugs, known as biosimilars. The bill limits the number of patents that the original drug manufacturer can use to block these biosimilar products in court, particularly for patents filed after the drug has been approved for four years. However, this limit does not apply to certain patents related to how the drug is used. Courts can allow more patents to be used if there is a good reason to do so.
The bill has been praised for its potential to lower drug costs for patients by facilitating the entry of more affordable biosimilar drugs into the market. Supporters argue that it encourages competition and innovation in the pharmaceutical industry, ultimately benefiting consumers who struggle with high medication prices.
Critics of the Affordable Prescriptions for Patients Act express concerns that limiting patent assertions could undermine the incentive for pharmaceutical companies to invest in new drug development. They argue that it may lead to a reduction in the quality of biologic drugs and could create legal uncertainties that might discourage innovation in the biotech sector.
The Affordable Prescriptions for Patients Act, sponsored by John Cornyn, does not exhibit direct industry overlaps with his top donor industries, which include Health Professionals and Retired individuals. While these industries have contributed significant amounts, totaling approximately $3.045 billion, they do not directly align with the subject matter of the bill, which focuses on prescription affordability. The absence of direct financial ties between the bill's objectives and the sponsor's top donors suggests a lower risk of conflicts of interest. Furthermore, the lobbying activity in this policy area includes various entities, but many contributions remain undisclosed, making it challenging to ascertain their influence on the bill's direction. However, the disclosed contributions from organizations like Marshfield Clinic Health System ($60,000) and the Coalition for the Use of Safe and Efficient Refrigerants ($20,000) do not indicate a significant conflict with the bill's intent.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| NATIONAL ASPHALT PAVEMENT ASSOCIATION | NATIONAL ASPHALT PAVEMENT ASSOCIATION | $150,000 |
| MARSHFIELD CLINIC HEALTH SYSTEM | MARSHFIELD CLINIC HEALTH SYSTEM | $60,000 |
| SOUTHERN IONICS | KEY IMPACT STRATEGIES | $30,000 |
| COALITION FOR THE USE OF SAFE AND EFFICIENT REFRIGERANTS | WILLIAMSON LAW + POLICY PLLC | $20,000 |
| NOLA EDUCATION, LLC | KEY IMPACT STRATEGIES | $10,000 |
| NATIONAL CONSUMER REPORTING ASSOCIATION | NATIONAL CONSUMER REPORTING ASSOCIATION | $5,000 |
| PUEBLO OF SANTA ANA | HOBBS, STRAUS, DEAN & WALKER, LLP | undisclosed |
| TIGERSWAN | ALPHA STRATEGIES, LLC | undisclosed |
| LWRC INTERNATIONAL, LLC | ALPHA STRATEGIES, LLC | undisclosed |
| NATIVE VILLAGE OF EYAK | HOBBS, STRAUS, DEAN & WALKER, LLP | undisclosed |
| HEALTHCARE FINANCIAL MANAGEMENT ASSOCIATION | HEALTHCARE FINANCIAL MANAGEMENT ASSOCIATION | undisclosed |
| RMS OF GEORGIA, LLC D/B/A CHOICE REFRIGERANTS | WILLIAMSON LAW + POLICY PLLC | undisclosed |
| BRISTOL BAY AREA HEALTH CORP | HOBBS, STRAUS, DEAN & WALKER, LLP | undisclosed |
| COUNCIL OF ATHABASCAN TRIBAL GOVERNMENTS | HOBBS, STRAUS, DEAN & WALKER, LLP | undisclosed |
| ALEUTIAN PRIBILOF ISLANDS ASSOCIATION | HOBBS, STRAUS, DEAN & WALKER, LLP | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding John Cornyn, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
